Actively Recruiting
Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for Tumors Likely to Express High Levels of CAIX
Led by Peking University First Hospital · Updated on 2026-05-14
200
Participants Needed
1
Research Sites
25 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the diagnostic value of a new protein-specific probe called 18F-T2 in PET/CT imaging for people with solid tumors that are likely to express high levels of CAIX protein. The study will also assess how safe and tolerable the 18F-T2 injection is, as well as measure its radiation dosage. This research is important to better understand how well 18F-T2 can detect these tumors compared to standard imaging techniques. Participants with tumors suspected to express high levels of CAIX will receive an intravenous injection of 18F-T2. About an hour after the injection, PET/CT imaging will be performed to capture detailed images of the tumors. Within one week, participants will also undergo a whole-body PET/CT scan using 18F-FDG, a commonly used imaging agent, to allow comparison between the two imaging methods. During the study, participants will be monitored for any adverse events within 24 hours after the 18F-T2 injection to evaluate safety and tolerability. Researchers will measure the diagnostic sensitivity and specificity of 18F-T2 PET/CT for detecting CAIX-positive tumors. They will also assess uptake values in tumors on both 18F-T2 and 18F-FDG scans, analyze the correlation between 18F-T2 uptake and CAIX expression in tissue samples, and evaluate radiation dosimetry. The study will continue until one month after completion for outcome assessments.
CONDITIONS
Brief Title
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written and voluntarily given Informed Consent
- Male or female 18 years of age or older at time of consent
- Ability to understand the study and comply with protocol requirements
- Histologically confirmed or suspected tumors likely to express CAIX protein, including but not limited to Clear Cell Renal Cell Cancer, Urothelial Carcinoma, Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Head and Neck Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer, Endometrial Cancer, Von Hippel Lindau Disease
You will not qualify if you...
- Serious non-malignant diseases such as psychiatric, infectious, autoimmune, or metabolic conditions that may interfere with study objectives or safety
- Mental impairment affecting ability to give informed consent and comply with study requirements
- Female who is pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 week
Participants receive an intravenous injection of 18F-T2 followed by PET/CT imaging. They also undergo a whole-body 18F-FDG PET/CT scan within a one-week period.
2 visits (in-person)
Duration - Up to 1 month
Participants are observed for safety and diagnostic outcomes up to 1 month after imaging procedures.
1 follow-up visit (in-person or remote)
Trial Site Locations
Total: 1 location
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
Actively Recruiting
Research Team
K
Keting Tong
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here